Paper17616675
Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
Sizemore S and 4 others. Cancer Res, 2007. Cited by 116 papers, by iCite.
Cite this record
ConductScience Library. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Papers, record 17616675. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17616675
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Cytoskeletal Proteins | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Prostatic Neoplasms | Major topic |
| Sialoglycoproteins | Major topic |
| Cell Line, Tumor | |
| Female | |
| Humans | |
| MAP Kinase Signaling System | |
| Male | |
| Matrix Metalloproteinase 1 | |
| Matrix Metalloproteinase 9 | |
| Neoplasm Invasiveness | |
| Phenotype | |
| Phosphatidylinositol 3-Kinases | |
| Ezrin |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA88164 | NCI NIH HHS | United States | R01CA088164 | PubMed and NIH | NIH RePORTER |
| R01 CA087728 | NCI NIH HHS | United States | R01CA087728 | PubMed | NIH RePORTER |
| CA98683 | NCI NIH HHS | United States | R01CA098683 | PubMed and NIH | NIH RePORTER |
| P50 CA089019 | NCI NIH HHS | United States | P50CA089019 | PubMed | NIH RePORTER |
| R01 CA100748 | NCI NIH HHS | United States | R01CA100748 | PubMed | NIH RePORTER |
Cited by84
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 116 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42936515 | Claudin 1 promotes blood-borne metastasis by modulating the Src/Ezrin signaling pathway in high-CLDN1 triple-negative breast cancer model. | Mol Cell Oncol | 2026 | https://conductscience.org/library/papers/42936515 | PubMed |
| 42699358 | Monocyte-Macrophage Lineages in Cancer: Biology, Plasticity, and Therapeutic Targeting. | Cancer Biome Target Ther | 2026 | https://conductscience.org/library/papers/42699358 | PubMed |
| 41854948 | PODXL2 Promotes Cholangiocarcinoma Progression via Interactions with Ezrin and Activation of the MAPK/ERK1/2 and PI3K/AKT Signaling Pathways. | Dig Dis Sci | 2026 | https://conductscience.org/library/papers/41854948 | PubMed |
| 41462970 | Podocalyxin, Isthmin-1, and Pentraxin-3 Immunoreactivities as Emerging Immunohistochemical Markers of Fibrosis in Chronic Hepatitis B. | Biomedicines | 2025 | https://conductscience.org/library/papers/41462970 | PubMed |
| 41059339 | Posttranslational microtubule modification alters podocalyxin-trafficking in epithelial cells. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/41059339 | PubMed |
| 40953793 | Hyperactive PDGFRβ signaling induces cataractogenesis via TGFβ and STAT5-IGF1. | Dev Biol | 2025 | https://conductscience.org/library/papers/40953793 | PubMed |
| 40071026 | Rhoifolin: A promising flavonoid with potent cytotoxic and anticancer properties: molecular mechanisms and therapeutic potential. | EXCLI J | 2025 | https://conductscience.org/library/papers/40071026 | PubMed |
| 39294825 | Tumor endothelium-derived PODXL correlates with immunosuppressive microenvironment and poor prognosis in cervical cancer patients receiving radiotherapy or chemoradiotherapy. | Biomark Res | 2024 | https://conductscience.org/library/papers/39294825 | PubMed |
| 39272901 | The RAL Small G Proteins Are Clinically Relevant Targets in Triple Negative Breast Cancer. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39272901 | PubMed |
| 39262484 | Has_circ_0002360 promotes the progression of lung adenocarcinoma by activating miR-762 and regulating PODXL expression. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/39262484 | PubMed |
| 39186674 | CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression. | Cancer Res | 2024 | https://conductscience.org/library/papers/39186674 | PubMed |
| 39055653 | Role of actin-binding proteins in prostate cancer. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39055653 | PubMed |
| 38376199 | Keratan sulfate, an electrosensory neurosentient bioresponsive cell instructive glycosaminoglycan. | Glycobiology | 2024 | https://conductscience.org/library/papers/38376199 | PubMed |
| 38203331 | A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38203331 | PubMed |
| 37304805 | Ezrin Immunoexpression in Prostate Adenocarcinomas. | Curr Health Sci J | 2022 | https://conductscience.org/library/papers/37304805 | PubMed |
| 36735782 | Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. | Sci Adv | 2023 | https://conductscience.org/library/papers/36735782 | PubMed |
| 35992085 | Multifaceted role of RNA editing in promoting loss-of-function of PODXL in cancer. | iScience | 2022 | https://conductscience.org/library/papers/35992085 | PubMed |
| 35930100 | MiR-199a-5p-containing macrophage-derived extracellular vesicles inhibit SMARCA4 and alleviate atherosclerosis by reducing endothelial cell pyroptosis. | Cell Biol Toxicol | 2023 | https://conductscience.org/library/papers/35930100 | PubMed |
| 35711462 | Podocalyxin Expressed in Antigen Presenting Cells Promotes Interaction With T Cells and Alters Centrosome Translocation to the Contact Site. | Front Immunol | 2022 | https://conductscience.org/library/papers/35711462 | PubMed |
| 35491830 | The Lectin LecB Induces Patches with Basolateral Characteristics at the Apical Membrane to Promote Pseudomonas aeruginosa Host Cell Invasion. | mBio | 2022 | https://conductscience.org/library/papers/35491830 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EZR | 7430 | Swiss-Prot's references | https://conductscience.org/library/genes/7430 | NCBI Gene |
| PODXL | 5420 | Swiss-Prot's references | https://conductscience.org/library/genes/5420 | NCBI Gene |
| MMP1 | 4312 | PubTator's text mining | https://conductscience.org/library/genes/4312 | NCBI Gene |
| MMP9 | 4318 | PubTator's text mining | https://conductscience.org/library/genes/4318 | NCBI Gene |
| PIK3R1 | 5295 | PubTator's text mining | https://conductscience.org/library/genes/5295 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17616675
GET https://conductscience.org/api/papers/v1/17616675/cited_by?page=2